Data center capital expenditures are reaching record highs. A significant portion of data center spending is allocated to ...

Hiding in Plain Sight Quantum computing has surged from theoretical curiosity to a transformative frontier, promising to ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Researchers discovered how to flip the structure of complex drug compounds using a simple reagent, offering a game-changing ...

Cadence Design Systems CDNS stock has rallied 23.8% over the past three months. The stock closed last trading session at $322 ...

Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial ...

Water molecules represent a powerful but largely underappreciated foothold in drug binding studies. See how ColdBrew, an algorithm designed by corresponding author Marcus Fischer, PhD (left) and first ...

Drug discovery startup Synfini Inc. said today it has closed on an $8.9 million expansion funding round led by JSL Health ...

Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

AI has enhanced precision, power and performance in drug development and manufacturing.

The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc. offered an update on its non-binding takeover proposal at 11 euros a ...

The Case for SDGR Stock Schrodinger, on the other hand, uses its differentiated, physics-based computational platform to enable the discovery of high-quality, novel molecules for drug development.